Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Inv. presentation
Employment agrmnt
Director departure
Appointed director
|
|
UNIGENE LABORATORIES INC (UGNE)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/05/2012 |
8-K
| Investor presentation |
| 03/08/2012 |
8-K
| Investor presentation |
| 01/09/2012 |
8-K
| Investor presentation |
| 11/16/2011 |
8-K
| Form 8-K - Current report |
| 11/09/2011 |
8-K
| Form 8-K - Current report |
| 10/06/2011 |
8-K
| Investor presentation |
| 09/12/2011 |
8-K
| Investor presentation |
| 08/09/2011 |
8-K
| Form 8-K - Current report |
| 08/08/2011 |
8-K
| Investor presentation |
| 03/15/2011 |
8-K
| Investor presentation|
Docs:
|
"Presentation Materials",
"Unigene Doses First Patient in Phase 2 Oral PTH Study for the Treatment of Osteoporosis in Postmenopausal Women -Company expects to complete patient enrollment in the first half of 2011; Top-line results expected before year end- March 15, 2011 –BOONTON, N.J. -- -- Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today the dosing of the first subject in a Phase 2 study with an experimental oral parathyroid hormone analog for the treatment of osteoporosis in postmenopausal women. Unigene is developing its oral PTH in collaboration with GlaxoSmithKline as part of an exclusive worldwide licensing agreement Ashleigh Palmer, President and Chief Executive Officer of Unigene Laboratories, Inc., said, “The initiation o..." |
|
| 02/14/2011 |
8-K
| Investor presentation |
| 09/14/2010 |
8-K
| Form 8-K - Current report |
| 03/25/2010 |
8-K
| Investor presentation |
|
|